0001613103Medtronic plcD02 XH02false00016131032020-08-252020-08-250001613103us-gaap:CommonStockMember2020-08-252020-08-250001613103mdt:SeniorNotes2019Due2021FloatingMember2020-08-252020-08-250001613103mdt:SeniorNotes2019Due2021Member2020-08-252020-08-250001613103mdt:SeniorNotes2019Due2022Member2020-08-252020-08-250001613103mdt:SeniorNotes2019Due20230.375PercentMember2020-08-252020-08-250001613103mdt:SeniorNotes2019Due2025Member2020-08-252020-08-250001613103mdt:SeniorNotes2019Due2027Member2020-08-252020-08-250001613103mdt:SeniorNotes2019Due20311.625PercentMember2020-08-252020-08-250001613103mdt:SeniorNotes2019Due20311.00PercentMember2020-08-252020-08-250001613103mdt:SeniorNotes2019Due20392.250PercentMember2020-08-252020-08-250001613103mdt:SeniorNotes2019Due20391.50PercentMember2020-08-252020-08-250001613103mdt:SeniorNotes2019Due2049Member2020-08-252020-08-25

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
_____________________________ 
FORM 8-K
 _____________________________ 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 25, 2020
 _____________________________ 
Medtronic Public Limited Company
(Exact name of Registrant as Specified in its Charter)
  _____________________________ 
 
Ireland 1-36820 98-1183488
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)

20 On Hatch, Lower Hatch Street
Dublin 2, Ireland
(Address of principal executive offices) (Zip Code)
+353 1 438-1700
(Registrant’s telephone number, including area code)
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))













Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange
Floating Rate Notes due 2021MDT/21New York Stock Exchange
0.000% Senior Notes due 2021MDT/21ANew York Stock Exchange
0.000% Senior Notes due 2022MDT/22BNew York Stock Exchange
0.375% Senior Notes due 2023MDT/23BNew York Stock Exchange
0.25% Senior Notes due 2025MDT/25New York Stock Exchange
1.125% Senior Notes due 2027MDT/27New York Stock Exchange
1.625% Senior Notes due 2031MDT/31New York Stock Exchange
1.00% Senior Notes due 2031MDT/31ANew York Stock Exchange
2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange
1.50% Senior Notes due 2039MDT/39BNew York Stock Exchange
1.75% Senior Notes due 2049MDT/49New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.






Item 2.02.Results of Operations and Financial Condition

On August 25, 2020, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its first quarter fiscal year 2021 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.
 
Item 9.01.      Exhibits.
(d) List of Exhibits
Exhibit Number  Description
  








SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
   MEDTRONIC PUBLIC LIMITED COMPANY
  By /s/ Karen L. Parkhill
Date: August 25, 2020   Karen L. Parkhill
   Executive Vice President and Chief Financial Officer







EXHIBIT INDEX

Exhibit Number  Description